Researchers found that new pricing models for diabetes medications could significantly reduce costs for Medicare beneficiaries. Starting January 1, 2027, Lilly’s medications, including Zepbound® and Mounjaro®, will be available through Medicare Part D with a capped out-of-pocket cost of $50 per month after the deductible is met. This means that for many people managing diabetes, accessing these essential medications will become more affordable, potentially easing the financial burden of treatment.

This change matters because it directly impacts the health and well-being of older adults who rely on these medications to manage their diabetes. By capping monthly costs, individuals can better plan their budgets and ensure they continue their treatment without interruption. The new model also limits upfront costs to $245 per month, making it easier for people to access their medications even before meeting their deductible. This is particularly important for those who may struggle with the high costs of diabetes care.

The CMMI BALANCE Model is part of a broader initiative by the Centers for Medicare and Medicaid Services to improve access to essential medications for Medicare beneficiaries. While this model is promising, it is still in the implementation phase, and the full effects will be seen once it takes effect in 2027. Until then, it’s important for individuals to stay informed about their Medicare options and any changes that may affect their access to medications.

For those managing diabetes, it’s wise to discuss these upcoming changes with your healthcare provider. Understanding your Medicare plan and the new pricing models can help you navigate your treatment options and ensure you get the medications you need at a more manageable cost.

Source: investor.lilly.com